Efficacy Study of Acupuncture on Asymptomatic Hyperuricemia (NCT05406830) | Clinical Trial Compass
UnknownNot Applicable
Efficacy Study of Acupuncture on Asymptomatic Hyperuricemia
China180 participantsStarted 2022-07-13
Plain-language summary
hyperuricemia (HUA) is an important risk factor for various chronic diseases, such as gout, and the current treatment programs for HUA are not ideal. It is urgent to find new methods to prevent and treat HUA and to carry out early clinical intervention. Acupuncture is commonly used for the treatment of HUA, while the evidence for its efficacy is still uncertain. This clinical trial aimed to evaluate the efficacy and safety of manual acupuncture for asymptomatic HUA.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosed as hyperuricemia; and
* Fasting blood uric acid level ≥ 7-11.0 mg/dL after 1 month of low-purine diet; and
* Without history of gouty arthritis; and
* Without drug treatment for hyperuricemia or stop uric acid-lowering drug treatment ≥12 weeks; and
* 18.5kg/m2≤BMI≤30.0kg/ m2; and
* Able to signing a informed consent.
Exclusion Criteria:
* Those who are using or have used one of the following drugs for the treatment of hyperuricemia 12 weeks before eligibility evaluation, such as: allopurinol, benzbromarone, probesulfan, bugelone, toppirosteine, Busotan; and
* Patients are using or used other drugs that affect uric acid metabolism in the past 12 weeks, such as: thiazide diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, compound reserpine, pyrazinamide, nitrates fendipine, propranolol, and benzbromarone; and
* Patients have history of gouty arthritis; and
* Combined with secondary hyperurmicema, such as bone marrow and lymphoproliferative diseases, tumor radiotherapy and chemotherapy, liver cirrhosis and drug-induced hyperurmicema; and
* Combined with one of the following comorbidities: hypertension, diabetes, stroke, coronary heart disease, severe liver and kidney damage (≥CKD stage 2, or high creatinine, urea, glutamate, glutamate ≥ 2 times of the limit of clinical normal values); and
* Combined with severe neuropsychological diseases, such as severe anxiety, depression, and intellectual disability; and
* Pr…
What they're measuring
1
Changes in the mean level of serum uric acid from baseline.
Timeframe: At baseline, and at 8 weeks after randomization.